RecruitingNCT01281735
International Chronic Myeloid Leukemia Pediatric Study
INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents
Sponsor
Poitiers University Hospital
Enrollment
750 participants
Start Date
Jan 1, 2011
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to describe and characterize CML in a large pediatric cohort of patients.
Eligibility
Max Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This international registry study collects data on children and teenagers diagnosed with chronic myeloid leukemia (CML) — a type of blood cancer — to better understand how this disease behaves in young patients and how they respond to treatment.
**You may be eligible if...**
- You are under 18 years old at the time of CML diagnosis
- You have been diagnosed with Philadelphia chromosome-positive or BCR-ABL-positive chronic myeloid leukemia, at any disease phase
**You may NOT be eligible if...**
- You were 18 years or older at the time of your CML diagnosis
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(20)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01281735
Related Trials
Asciminib RMP Study
NCT0594352217 locations
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT068177201 location
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069745 locations
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT0530437745 locations
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
NCT035338162 locations